Enable AccessibilityEnable Accessibility

Share Dealing By A Person Discharging Managerial Responsibility

December 30, 2011


Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company was notified on December 29, 2011, that Sylvie Gregoire had exercised, on the same day, SAR Awards granted under the Shire Portfolio Share Plan over Shire American Depository Shares (“ADSs”). The resulting ADSs were sold on the NASDAQ. One ADS is equal to three Shire ordinary shares.

Number of
ADSs exercised

Exercise price

Number of ADSs
released and sold

Sale price









Following the above transactions, Sylvie Gregoire holds 1,218 ADSs and awards of Stock Appreciation Rights, Performance Shares and Restricted Shares over 104,766 ADSs.

This notification relates to disclosures made in accordance with 3.1.4(R)(1)(a) of the Disclosure and Transparency Rules.

Tony Guthrie
Deputy Company Secretary

For further information please contact:

Investor Relations   

Eric Rojas ([email protected])
+1 781 482 0999

Sarah Elton-Farr ([email protected])
+44 1256 894157

Notes to editors


Shire’s strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician.  Shire focuses its business on attention deficit hyperactivity disorder, human genetic therapies, gastrointestinal diseases and regenerative medicine as well as opportunities in other therapeutic areas to the extent they arise through acquisitions.  Shire’s in-licensing, merger and acquisition efforts are focused on products in specialist markets with strong intellectual property protection and global rights.  Shire believes that a carefully selected and balanced portfolio of products with strategically aligned and relatively small-scale sales forces will deliver strong results.

For further information on Shire, please visit the Company’s website: www.shire.com.